INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grant will fund proof-of-concept studies for XPro1595 therapy

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS

Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 published in Alzheimer's Research & Therapy Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 published in Alzheimer's Research & Therapy

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

News for INmune Bio Inc Stock (INMB)